AbbVie Inc (ABBV)vsWaystar Holding Corp. Common Stock (WAY)
ABBV
AbbVie Inc
$203.89
+3.14%
HEALTHCARE · Cap: $351.47B
WAY
Waystar Holding Corp. Common Stock
$25.27
+0.16%
HEALTHCARE · Cap: $4.88B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5464% more annual revenue ($61.16B vs $1.10B). WAY leads profitability with a 10.2% profit margin vs 6.9%. WAY trades at a lower P/E of 41.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WAY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-24.9%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+3.5%
Fair Value
$24.59
Current Price
$25.27
$0.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 23.6%
Revenue surging 24.3% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Distress zone — elevated risk
ROE of 3.2% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.47 suggests the stock is reasonably priced for its growth.
Bull Case : WAY
The strongest argument for WAY centers on Price/Book, Debt/Equity, Operating Margin. Revenue growth of 24.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 84.2x leaves little room for execution misses.
Bear Case : WAY
The primary concerns for WAY are Altman Z-Score, Return on Equity, Piotroski F-Score. A P/E of 41.7x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while WAY is a growth play — different risk/reward profiles.
WAY is growing revenue faster at 24.3% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Waystar Holding Corp. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Waystar Holding Corp. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?